Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
This trial is comparing the safety and efficacy of a new single tablet regimen (MK1439A) to current PI boosted regimen in HIV infected adults that are suppressed on their medications.
Who may be Eligible
Adult patients with HIV who are currently taking Atazanavir, Kaletra or Darunavir for 6 months; Viral load is undetectable; Not be pregnant or planning to become pregnant or father a child during the study; Patient with acute hepatitis are excluded; Patients with chronic hepatitis are permitted as long as their therapy does not have activity against HIV; Must have stable maintenance labs (kidney, liver, hematology and cardiac function); No history of NNRTI use or virologic failure.